Bank of New York Mellon
CALA

Bank of New York Mellon’s Calithera Biosciences, Inc CALA Stock Holding History

Bank of New York Mellon’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,554
Closed -$13K – 4762
2022
Q1 		$13K Hold
1,554
– – ﹤0.01% 4635
2021
Q4 		$21K Hold
1,554
– – ﹤0.01% 4584
2021
Q3 		$68K Hold
1,554
– – ﹤0.01% 4394
2021
Q2 		$65K Sell
1,554
-9,938
-86% -$437K ﹤0.01% 4290
2021
Q1 		$556K Sell
11,492
-142
-1% -$8.26K ﹤0.01% 3629
2020
Q4 		$1.14M Sell
11,634
-664
-5% -$58.2K ﹤0.01% 3185
2020
Q3 		$849K Sell
12,298
-124
-1% -$10.8K ﹤0.01% 3217
2020
Q2 		$1.31M Buy
12,422
+1,674
+16% +$199K ﹤0.01% 2946
2020
Q1 		$954K Buy
10,748
+1,592
+17% +$190K ﹤0.01% 3019
2019
Q4 		$1.05M Buy
9,156
+814
+10% +$61.2K ﹤0.01% 3226
2019
Q3 		$516K Buy
8,342
+1,537
+23% +$123K ﹤0.01% 3523
2019
Q2 		$531K Buy
6,805
+374
+6% +$42.4K ﹤0.01% 3569
2019
Q1 		$866K Buy
6,431
+75
+1% +$7.88K ﹤0.01% 3277
2018
Q4 		$510K Sell
6,356
-1,935
-23% -$191K ﹤0.01% 3468
2018
Q3 		$871K Buy
8,291
+192
+2% +$18.3K ﹤0.01% 3352
2018
Q2 		$810K Buy
8,099
+1,217
+18% +$138K ﹤0.01% 3366
2018
Q1 		$867K Buy
6,882
+248
+4% +$38.7K ﹤0.01% 3295
2017
Q4 		$1.11M Buy
6,634
+1,134
+21% +$290K ﹤0.01% 3186
2017
Q3 		$1.73M Buy
5,500
+95
+2% +$30K ﹤0.01% 2923
2017
Q2 		$1.6M Buy
5,405
+3,771
+231% +$1.01M ﹤0.01% 2974
2017
Q1 		$377K Buy
1,634
+243
+17% +$42K ﹤0.01% 3669
2016
Q4 		$90K Buy
1,391
+548
+65% +$34.2K ﹤0.01% 4044
2016
Q3 		$55K Sell
843
-151
-15% -$9.73K ﹤0.01% 4130
2016
Q2 		$74K Sell
994
-1,292
-57% -$129K ﹤0.01% 4114
2016
Q1 		$260K Sell
2,286
-285
-11% -$32.3K ﹤0.01% 3698
2015
Q4 		$394K Buy
2,571
+899
+54% +$135K ﹤0.01% 3623
2015
Q3 		$181K Sell
1,672
-387
-19% -$50.2K ﹤0.01% 3940
2015
Q2 		$294K Buy
2,059
+492
+31% +$114K ﹤0.01% 3784
2015
Q1 		$515K Buy
1,567
+75
+5% +$26.7K ﹤0.01% 3593
2014
Q4 		$603K Buy
+1,492
New +$390K ﹤0.01% 3539

Other funds holding CALA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon's CALA Position: Q2 2022 in Review

Bank of New York Mellon sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 1,554 shares — an estimated $13K sold.

Bank of New York Mellon first reported a position in CALA in Q4 2014 and held it in 30 quarters. The position peaked at $1.73M in Q3 2017. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

  • Bank of New York Mellon reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 1,554 Calithera Biosciences, Inc shares in Q2 2022, an estimated $13K.
  • Bank of New York Mellon first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 30 quarters.
  • Bank of New York Mellon's Calithera Biosciences, Inc position peaked at $1.73M in Q3 2017.
  • 28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.